Rational design of RAR‐selective ligands revealed by RARβ crystal stucture
Open accessThe DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
The crystal structure of the ligand‐binding domain of RARβ, a suspect tumour suppressor, reveals important features that distinguish it from the two other RAR isotypes. The most striking difference is an extra cavity allowing RARβ to bind more bulky agonists. Accordingly, we identified a ligand that shows RARβ selectivity with a 100‐fold higher affinity to RARβ than to α or γ isotypes. The structural differences between the three RAR ligand‐binding pockets revealed a rationale explaining how a single retinoid can be at the same time an RARα, γ antagonist and an RARβ agonist. In addition, we demonstrate how to generate an RARβ antagonist by gradually modifying the bulkiness of a single substitution. Together, our results provide structural guidelines for the synthesis of RARβ‐selective agonists and antagonists, allowing for the first time to address pharmacologically the tumour suppressor role of RARβ in vitro and in animal models.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Métivier, R., Penot, G., Hübner, M. R., Reid, G., Brand, H., Koš, M., & Gannon, F. (2003) · Cell · doi:10.1016/s0092-8674(03)00934-6 · Cited by 1,431
The promise of retinoids to fight against cancer
Altucci, L., & Gronemeyer, H. (2001) · Nature Reviews Cancer · doi:10.1038/35106036 · Cited by 773 · cited 3×
“…activities exerted by the three RARs, which are the basis for the well-established cancer therapeutic and cancer preventive activity of retinoids (Altucci & Gronemeyer, 2001; Sun & Lotan, 2002), assess the role of the suspect tumour suppressor RARb and will aid in generating novel retinoids with…”
BackgroundSelf-citation
Cited by
Principles for modulation of the nuclear receptor superfamily
Gronemeyer, H., Gustafsson, J.-Å., & Laudet, V. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1551 · Cited by 1,226
Self-citationOverview of nomenclature of nuclear receptors
Germain, P., Staels, B., Dacquet, C., Spedding, M., & Laudet, V. (2006) · Pharmacological Reviews · doi:10.1124/pr.58.4.2 · Cited by 688
Self-citationRAR and RXR modulation in cancer and metabolic disease
Altucci, L., Leibowitz, M. D., Ogilvie, K. M., de Lera, A. R., & Gronemeyer, H. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2397 · Cited by 517
Self-citationInternational Union of Pharmacology. LXIII. Retinoid X receptors
Germain, P., Chambon, P., Eichele, G., Evans, R. M., Lazar, M. A., Leid, M., De Lera, A. R., Lotan, R., Mangelsdorf, D. J., & Gronemeyer, H. (2006) · Pharmacological Reviews · doi:10.1124/pr.58.4.7 · Cited by 496
Self-citationRetinoic acid receptors: From molecular mechanisms to cancer therapy
di Masi, A., Leboffe, L., De Marinis, E., Pagano, F., Cicconi, L., Rochette-Egly, C., Lo-Coco, F., Ascenzi, P., & Nervi, C. (2015) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2014.12.003 · Cited by 403
International Union of Pharmacology. LX. Retinoic Acid Receptors
Germain, P., Chambon, P., Eichele, G., Evans, R. M., Lazar, M. A., Leid, M., De Lera, A. R., Lotan, R., Mangelsdorf, D. J., & Gronemeyer, H. (2006) · Pharmacological Reviews · doi:10.1124/pr.58.4.4 · Cited by 397
Self-citationLee, H., Fenster, R. J., Pineda, S. S., Gibbs, W. S., Mohammadi, S., Davila-Velderrain, J., Garcia, F. J., Therrien, M., Novis, H. S., Gao, F., et al. (2020) · Neuron · doi:10.1016/j.neuron.2020.06.021 · Cited by 279
Design of selective nuclear receptor modulators: RAR and RXR as a case study
de Lera, A. R., Bourguet, W., Altucci, L., & Gronemeyer, H. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2398 · Cited by 270
Self-citationFunctions, Therapeutic Applications, and Synthesis of Retinoids and Carotenoids
Álvarez, R., Vaz, B., Gronemeyer, H., & de Lera, Á. R. (2014) · Chemical Reviews · doi:10.1021/cr400126u · Cited by 260
Self-citationRetinoic Acid Induces Blood–Brain Barrier Development
Mizee, M. R., Wooldrik, D., Lakeman, K. A. M., van het Hof, B., Drexhage, J. A. R., Geerts, D., Bugiani, M., Aronica, E., Mebius, R. E., Prat, A., et al. (2013) · The Journal of Neuroscience · doi:10.1523/jneurosci.1338-12.2013 · Cited by 203
“BMS453 has confirmed activity in vitro (Germain et al., 2004) and in vivo (Matt et al.”
BackgroundStructural and functional insights into nuclear receptor signaling
Jin, L., & Li, Y. (2010) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2010.08.007 · Cited by 112
Dissecting the retinoid-induced differentiation of F9 embryonal stem cells by integrative genomics
Mendoza‐Parra, M. A., Walia, M., Sankar, M., & Gronemeyer, H. (2011) · Molecular Systems Biology · doi:10.1038/msb.2011.73 · Cited by 91
“…(Chiba et al, 1997a, b), and affect global gene expression profiling even in absence of any treatment (Su and Gudas, 2008), we used RAR subtype-selective agonists (Gehin et al, 1999; Germain et al, 2004; de Lera et al, 2007) to define selective and promiscuous functionalities of RAR subtypes.”
MethodSelf-citationRegulation of RXR-RAR Heterodimers by RXR- and RAR-Specific Ligands and Their Combinations
le Maire, A., Teyssier, C., Balaguer, P., Bourguet, W., & Germain, P. (2019) · Cells · doi:10.3390/cells8111392 · Cited by 88
“As a result, proteolysis assays can be used to monitor ligand binding and evaluate binding affinity as the proteolytic resistance of protected fragments is dependent on ligand concentration [53].”
BackgroundMethodSelf-citationOsz, J., Brélivet, Y., Peluso-Iltis, C., Cura, V., Eiler, S., Ruff, M., Bourguet, W., Rochel, N., & Moras, D. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1118192109 · Cited by 84
Self-citationPorté, S., Xavier Ruiz, F., Giménez, J., Molist, I., Alvarez, S., Domínguez, M., Alvarez, R., de Lera, A. R., Parés, X., & Farrés, J. (2013) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2012.11.014 · Cited by 38
Samarut, E., Amal, I., Markov, G. V., Stote, R., Dejaegere, A., Laudet, V., & Rochette-Egly, C. (2011) · Molecular Biology and Evolution · doi:10.1093/molbev/msr035 · Cited by 26
Chebaro, Y., Amal, I., Rochel, N., Rochette-Egly, C., Stote, R. H., & Dejaegere, A. (2013) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1003012 · Cited by 25
“The nuclear receptor RARa is an important player in the regulation of gene transcription and many structure-based studies corroborated the role of ligand binding in the regulatory mechanisms [33–36].”
Background
Metadata
- Authors
- Germain, P., Kammerer, S., Pérez, E., Peluso‐Iltis, C., Tortolani, D., Zusi, F. C., Starrett, J., Lapointe, P., Daris, J., Marinier, A., de Lera, A. R., Rochel, N., & Gronemeyer, H.
- Venue
- EMBO reports
- Published
- 2004-09
- Volume
- 5
- Issue
- 9
- Pages
- 877-882
- ISSN
- 1469-221X (ISSN-L)
- 1469-3178
- OpenAlex
- W2168116634
- Cited by
- 89
- References
- 2
- FWCI
- 2.08
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.